Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • S153: MECHANISMS OF TROMBOGENE...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
S153: MECHANISMS OF TROMBOGENESIS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA UNDER TREATMENT WITH PONATINIB AND OTHER TYROSINE KINASE INHIBITORS

S153: MECHANISMS OF TROMBOGENESIS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA UNDER TREATMENT WITH PONATINIB AND OTHER TYROSINE KINASE INHIBITORS

Bibliographic Details
Main Authors: Ernesto José Cuenca Zamora, Sonia Águila, María José Lis, Maria Carmen Garcia Hernandez, María Jose Fernández, María Soledad Noya Pereira, Elvira Mora Castera, Luis Palomera Bernal, Maria Alicia Senin Magan, Raúl Pérez López, Manuel Perez Encinas, Anna Angona Figueras, José Manuel Puerta, Rolando Vallansot, Venancio Conesa Garcia, Juan Carlos Hernandez-Boluda, Ana Rosell Mas, Montserrat Cortés, Guillermo Ortí, Blanca Xicoy Cirici, Gonzalo Carreño Gomez-Tarragona, Pilar Giraldo, Maria L Lozano, Valentin Garcia Gutierrez, Francisca Ferrer-Marín, On Behalf of Spanish Group of Chronic Myeloid Leukemia (Gelmc)
Format: Article
Language:English
Published: Wiley 2023-08-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/01.HS9.0000967524.87606.24
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

http://journals.lww.com/10.1097/01.HS9.0000967524.87606.24

Similar Items

  • P680: PONATINIB 15 MG AS CONSOLIDATION PRIOR TO TREATMENT FREE REMISSION IN CHRONIC MYELOID LEUKEMIA
    by: Valentin Garcia Gutierrez, et al.
    Published: (2023-08-01)
  • A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia.
    by: Valentín García-Gutiérrez, et al.
    Published: (2017-01-01)
  • Critical review of clinical data and expert-based recommendations for the use of bosutinib in the treatment of chronic myeloid leukemia
    by: Valentín García-Gutiérrez, et al.
    Published: (2024-08-01)
  • Ponatinib‐induced ichthyosiform eruption
    by: Nicolas Kluger, et al.
    Published: (2021-08-01)
  • Ponatinib: A drug review
    by: Hasmukh Jain, et al.
    Published: (2019-01-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs